Soleno Therapeutics (SLNO) Free Cash Flow (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Free Cash Flow data on file, last reported at $26.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 179.31% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was $105.5 million, a 217.79% increase from a year earlier, with the FY2025 full-year figure at $46.7 million, up 167.41% from the prior year.
• Free Cash Flow for Q1 2026 stood at $26.0 million, down from $48.6 million in the prior quarter.
• Over the last five years, Free Cash Flow for SLNO reached as high as $48.6 million in Q4 2025 and fell as low as -$32.8 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$2.5 million across 5 years, with a median of -$6.3 million in 2023.
• Across the five-year window, Free Cash Flow plunged 280.09% in 2024 and surged 387.71% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$5.1 million in 2022, then dropped by 22.94% to -$6.3 million in 2023, then plunged by 280.09% to -$24.0 million in 2024, then soared by 302.71% to $48.6 million in 2025, then plunged by 46.6% to $26.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $26.0 million in Q1 2026, $48.6 million in Q4 2025, and $43.5 million in Q3 2025.